.Charles Baum, M.D., Ph.D., who oversaw Mirati Therapies' $ 5.8 billion sale to Bristol Myers Squibb in 2013, is taking the command of youthful biotech Terremoto Biosciences.Baum's "considerable expertise in drug development, as well as effective performance history beforehand high-impact medicines, are going to contribute," outbound CEO Peter Thompson, M.D., claimed in a July 25 release. Thompson will certainly retain his seat as board chairperson..Baum, a competent physician-scientist, was the creator, president as well as chief executive officer of oncology-focused Mirati. Before that, he aided build cancer cells medications at Pfizer and Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum will function as CEO at Terremoto, a provider creating small molecules to target disease-causing healthy proteins-- like those discovered in malignant cyst tissues-- making use of covalent connections. Existing treatments that utilize covalent connections primarily target the amino acid cysteine. Having said that, of the 20 amino acids that compose proteins, cysteine is the minimum usual. Terremoto is instead targeting some of the vital amino acids, lysine, which is actually discovered in nearly all proteins.By targeting amino acid lysine and other amino acids, Terremoto wants to address recently undruggable health conditions and develop first-in-class medications..The biotech, based in South San Francisco, brought up $75 thousand in collection A funding in 2022. A little greater than a year later, the biotech greater than increased that variety in a $175 million set B.